Catalyst Wire Dossier Catalyst Wire Dossier
FDA label_change · 2024-10-31

FDA Approved: XTAMPZA ER — Supplemental Application (Collegium Pharmaceutical, Inc.)

View source ↗

Summary

The FDA approved a supplemental application for XTAMPZA ER (oxycodone) from Collegium Pharmaceutical to update the product labeling. XTAMPZA ER is an extended-r…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • XTAMPZA ER (Oxycodone)

Snippet

SUPPL AP for XTAMPZA ER (OXYCODONE)